|

Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities

RECRUITINGSponsored by Christina Berr. MD
Actively Recruiting
SponsorChristina Berr. MD
Started2023-03-31
Est. completion2028-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

Pulmonary vein isolation is an established intervention for atrial fibrillation. Patients with a paroxysmal atrial fibrillation have no or only few comorbidities and a good prognosis in respect to their atrial fibrillation. In contrast, patients with persistent atrial fibrillation often suffer from relevant comorbidities and recurrence of atrial fibrillation is common. Left-atrial fibrosis and its electrophysiological consequences are involved in the recurrence rate, but pathophysiological mechanisms are yet to be better characterized. The study investigates relevant comorbidities to elucidated their effect on atrial fibrosis and recurrence rates of atrial fibrillation. Furthermore, the investigators evaluate the prevalence of these comorbidities.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* persistent atrial fibrillation, eligible for ablation
* BMI 19-40

Exclusion Criteria:

* valvular atrial fibrillation
* formerly ablation
* medication interfereing with measurements of atrial fibrosis
* known or treated comorbidities (OSAS, PA)

Conditions4

Atrial FibrillationHeart DiseasePrimary AldosteronismSleep Apnea

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.